Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.
Aged
Cell Differentiation
Dendritic Cell Sarcoma, Follicular
/ complications
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ complications
Lymph Nodes
/ pathology
Lymphoma, Large B-Cell, Diffuse
/ complications
Male
Middle Aged
Prognosis
Retrospective Studies
Sensitivity and Specificity
Syndrome
Tomography, X-Ray Computed
/ methods
Leukemia, lymphocytic, chronic, B cell
Lymphoma, large B cell, diffuse
Texture analysis
Tomography, X-ray-computed
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
14
03
2019
accepted:
28
05
2019
revised:
11
05
2019
pubmed:
27
6
2019
medline:
6
2
2020
entrez:
26
6
2019
Statut:
ppublish
Résumé
To test the hypothesis that both indolent and aggressive chronic lymphocytic leukemia (CLL) can be differentiated from diffuse large B cell lymphoma (DLBCL) of Richter syndrome (RS) by CT texture analysis (CTTA) of involved lymph nodes. We retrospectively included 52 patients with indolent CLL (26/52), aggressive CLL (8/52), and DLBCL of RS (18/52), who underwent standardized contrast-enhanced CT. In main lymphoma tissue, VOIs were generated from which CTTA features including first-, second-, and higher-order textural features were extracted. CTTA features were compared between the entire CLL group, the indolent CLL subtype, the aggressive CLL subtype, and DLBCL using a Kruskal-Wallis test. All p values were adjusted after the Bonferroni correction. ROC analyses for significant CTTA features were performed to determine cut-off values for differentiation between the groups. Compared with DLBCL of RS, CTTA of the entire CLL group showed significant differences of entropy heterogeneity (p < 0.001), mean intensity (p < 0.001), mean average (p = 0.02), and number non-uniformity gray-level dependence matrix (NGLDM) (p = 0.03). Indolent CLL significantly differed for entropy (p < 0.001), uniformity of heterogeneity (p = 0.02), mean intensity (p < 0.001), and mean average (p = 0.01). Aggressive CLL showed significant differences in mean intensity (p = 0.04). For differentiation between CLL and DLBCL of RS, cut-off values for mean intensity and entropy of heterogeneity were defined (e.g., 6.63 for entropy heterogeneity [aggressive CLL vs. DLBCL]; sensitivity 0.78; specificity 0.63). CTTA features of ultrastructure and vascularization significantly differ in CLL compared with that in DLBCL of Richter syndrome, allowing complementary to visual features for noninvasive differentiation by contrast-enhanced CT. • Richter transformation of CLL into DLBCL results in structural changes in lymph node architecture and vascularization that can be detected by CTTA. • First-order CT textural features including intensity and heterogeneity significantly differ between both indolent CLL and aggressive CLL and DLBCL of Richter syndrome. • CT texture analysis allows for noninvasive detection of Richter syndrome which is of prognostic value.
Identifiants
pubmed: 31236702
doi: 10.1007/s00330-019-06291-9
pii: 10.1007/s00330-019-06291-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6911-6921Références
Radiology. 2011 Oct;261(1):165-71
pubmed: 21813743
Eur Radiol. 2012 Apr;22(4):796-802
pubmed: 22086561
J Nucl Med. 2006 Aug;47(8):1267-73
pubmed: 16883004
Blood. 2011 Mar 24;117(12):3391-401
pubmed: 21266718
Am J Hematol. 2017 Sep;92(9):946-965
pubmed: 28782884
Radiology. 2013 Jan;266(1):177-84
pubmed: 23151829
J Comput Assist Tomogr. 2001 May-Jun;25(3):482-6
pubmed: 11351202
Eur Radiol. 2018 Apr;28(4):1520-1528
pubmed: 29164382
Ann Oncol. 2009 Mar;20(3):413-24
pubmed: 19088170
Blood. 1990 Apr 1;75(7):1414-21
pubmed: 2180492
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Cancer Imaging. 2013 Sep 23;13(3):400-6
pubmed: 24061266
Curr Treat Options Oncol. 2017 Jul;18(7):45
pubmed: 28670664
Mayo Clin Proc. 2012 Jun;87(6):571-80
pubmed: 22677077
Curr Hematol Malig Rep. 2016 Feb;11(1):43-51
pubmed: 26830086
Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):596-604
pubmed: 24469258
AJR Am J Roentgenol. 2012 Jun;198(6):1239-46
pubmed: 22623535
Cancer Imaging. 2013 Mar 26;13:140-9
pubmed: 23545171
Cancer. 2006 Sep 15;107(6):1294-302
pubmed: 16902984
Eur Radiol. 2017 Mar;27(3):1012-1020
pubmed: 27380902
Am J Surg Pathol. 2007 Oct;31(10):1605-14
pubmed: 17895764
Oncology (Williston Park). 2012 Dec;26(12):1146-52
pubmed: 23413591
Clin Radiol. 2012 Feb;67(2):157-64
pubmed: 21943720
Eur J Radiol. 2016 Jan;85(1):304-309
pubmed: 26515992
Leuk Lymphoma. 2014 Feb;55(2):233-4
pubmed: 23915194
Dis Esophagus. 2015 Feb-Mar;28(2):172-9
pubmed: 24460831
Ann Hematol. 2017 Jan;96(1):17-23
pubmed: 27677489
Leuk Lymphoma. 2014 Feb;55(2):314-9
pubmed: 23656196
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Haematologica. 2011 Jul;96(7):996-1001
pubmed: 21546504
Histopathology. 2016 Dec;69(6):1066-1076
pubmed: 27345622
Abdom Radiol (NY). 2017 May;42(5):1485-1492
pubmed: 28025654
Nucl Med Commun. 2017 Jul;38(7):563-576
pubmed: 28570287
Radiographics. 2017 Sep-Oct;37(5):1483-1503
pubmed: 28898189
Med J Armed Forces India. 2009 Oct;65(4):375-7
pubmed: 27408297
Radiology. 2013 Dec;269(3):801-9
pubmed: 23912620
Ann Nucl Med. 2011 Oct;25(8):536-46
pubmed: 21674240
Rofo. 2014 Jan;186(1):79-80
pubmed: 23975876